# The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma

> **NCT03576807** · PHASE1 · UNKNOWN · sponsor: **Xin Wang** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Lymphomas

## Interventions

- **DRUG:** CD20 CAR-T cells

## Key facts

- **NCT ID:** NCT03576807
- **Lead sponsor:** Xin Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-04
- **Primary completion:** 2019-04-03
- **Final completion:** 2020-04-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03576807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03576807, "The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03576807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*